Skip to main content
. Author manuscript; available in PMC: 2012 Jul 10.
Published in final edited form as: Semin Nucl Med. 2011 Jan;41(1):29–44. doi: 10.1053/j.semnuclmed.2010.08.005

Table 1.

18F-FDG PET clinical trials in prostrate cancer24-42.

Tracer(s) Patient
number		 Disease stage Study
objective		 Sensitivity Specificity Year Group
18F-FDG 48 Early Staging 81% NA 1996 Effert PJ, et al.
18F-FDG 13 Advanced Staging NA NA 1996 Yeh SD, et al.
18F-FDG 34 Advanced Staging 65% NA 1996 Shreve PD, et al
18F-FDG 18 Mixed Restaging NA NA 1999 Hofer C, et al
18F-FDG 44 Early Staging 64% NA 1999 Oyama N, et al.
18F-FDG 24 Early Staging 4% NA 2001 Liu IJ, et al.
18F-FDG 10 Advanced Restaging NA NA 2001 Oyama N, et al.
18F-FDG 42 Early Staging NA NA 2002 Oyama N, et al.
18F-FDG 17 Advanced Staging NA NA 2002 Morris MJ, et al.
18F-FDG 24 Advanced Re-staging 75% 100% 2003 Chang CH, et al.
18F-FDG 91 Mixed Restaging 31% NA 2005 Schoder H, et al
18F-FDG, 11C-methionine 10 Advanced Staging NA NA 1999 Mascapinlac HA, et al
18F-FDG, 11C-methionine 12 Advanced Staging 48% (72%) NA 2002 Nunez R, et al.
18F-FDG, 11C-acetate 15 (25) Mixed Staging NA NA 2003 Fricke E, et al
18F-FDG, 11C-acetate 18(22) Early Staging NA NA 2002 Oyama N, et al.
18F-FDG, 11C-acetate 46 Advanced Restaging NA NA 2003 Oyama N, et al.
18F-FDG, 11C-choline 100 Advanced Restaging 27% (47%) NA 2003 Picchio M, et
18F-FDG, 18F-FDHT 7 Advanced Staging 97% (78%) NA 2004 Larson SM, et al.
18F-FDG, 11C-choline, 26 Early Staging 73% 59% 2010 Watanabe H, et al.